Billiontoone (NASDAQ:BLLN) Price Target Cut to $130.00 by Analysts at JPMorgan Chase & Co.

Key Points

• JPMorgan lowered Billiontoone’s price target from $145 to $130 while maintaining an “overweight” rating; the new target implies 41.84% upside from the stock’s $91.65 closing price.
• Billiontoone reported quarterly revenue of $109.45 million and EPS of $0.15, matching consensus estimates, while reiterating fiscal 2026 revenue guidance of $450 million to $465 million.
• Shares fell sharply during Thursday’s trading session, and analysts’ overall view remains “Moderate Buy,” with an average price target of $126.71; insiders have sold about $23.5 million of stock over the past 90 days.

Billiontoone (NASDAQ:BLLN - Get Free Report) had its price objective decreased by analysts at JPMorgan Chase & Co. from $145.00 to $130.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 41.84% from the company's current price.

A number of other analysts have also weighed in on the company. Guggenheim initiated coverage on Billiontoone in a research note on Monday, June 29th. They issued a "buy" rating and a $125.00 target price for the company. BTIG Research cut their price target on Billiontoone from $142.00 to $130.00 and set a "buy" rating on the stock in a research note on Thursday. Finally, Weiss Ratings upgraded shares of Billiontoone from a "sell (d)" rating to a "sell (d+)" rating in a report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Billiontoone has an average rating of "Moderate Buy" and an average target price of $126.71.

Billiontoone Stock Performance

Shares of NASDAQ:BLLN traded down $58.32 during trading on Thursday, hitting $91.65. 3,740,246 shares of the stock were exchanged, compared to its average volume of 527,712. Billiontoone has a 1-year low of $61.96 and a 1-year high of $150.44. The company has a market capitalization of $4.21 billion and a price-to-earnings ratio of 166.64. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. The company's fifty day simple moving average is $116.73 and its 200-day simple moving average is $94.26.

Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, meeting analysts' consensus estimates of $0.15. The business had revenue of $109.45 million during the quarter. Sell-side analysts expect that Billiontoone will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Billiontoone news, insider Nancy Joann Johnson sold 10,582 shares of the stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $100.47, for a total value of $1,063,173.54. Following the completion of the transaction, the insider directly owned 21,900 shares in the company, valued at approximately $2,200,293. This trade represents a 32.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO David Tsao sold 20,000 shares of the business's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $102.27, for a total transaction of $2,045,400.00. Following the completion of the sale, the chief technology officer directly owned 1,000 shares in the company, valued at approximately $102,270. This represents a 95.24% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 202,049 shares of company stock valued at $23,496,861 over the last 90 days. 50.22% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently bought and sold shares of BLLN. Massachusetts Financial Services Co. MA bought a new position in shares of Billiontoone during the 4th quarter worth approximately $13,373,000. Baillie Gifford & Co. purchased a new position in shares of Billiontoone during the fourth quarter valued at approximately $103,786,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Billiontoone during the fourth quarter worth about $1,348,000. UBS Group AG purchased a new position in Billiontoone in the fourth quarter valued at about $2,586,000. Finally, Renaissance Capital LLC bought a new stake in Billiontoone in the 4th quarter valued at about $201,000.

More Billiontoone News

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Second-quarter revenue reached $109.45 million, while adjusted earnings of $0.15 per share matched Wall Street expectations. The results indicate continued demand for BillionToOne’s molecular diagnostics products. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
• Positive Sentiment: BTIG Research maintained a Buy rating, although it reduced its price target from $142 to $130. The revised target still indicates substantial potential upside, supporting the view that the long-term growth story remains intact. Benzinga analyst coverage
• Neutral Sentiment: BillionToOne reiterated fiscal 2026 revenue guidance of $450 million to $465 million, compared with analysts’ estimate of $453.3 million. The range is broadly in line with expectations but failed to provide the upward revision some investors may have anticipated. BillionToOne sinks as outlook unchanged despite surging revenue
• Negative Sentiment: The earnings release delivered a revenue beat narrative but only met consensus EPS, while the unchanged outlook raised concerns that growth may not be accelerating enough to justify BLLN’s premium valuation. BillionToOne Q2 Earnings Snapshot
• Negative Sentiment: CEO Oguzhan Atay reported sales totaling 45,000 shares, and insider Shan Riku Sakakibara sold an additional 4,000 shares. The transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their signaling value but still adding to near-term selling pressure.

Billiontoone Company Profile

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source